Modelling myocardial ischemia/reperfusion injury with inflammatory response in human ventricular cardiac organoids

Laihai Zhang,Yun Jiang,Wenwen Jia,Wenjun Le,Jie Liu,Peng Zhang,Huangtian Yang,Zhongmin Liu,Yang Liu
DOI: https://doi.org/10.1111/cpr.13762
IF: 8.755
2024-10-10
Cell Proliferation
Abstract:We obtained human ventricular cardiac organoids from hiPSCs by inhibiting the retinoic acid signaling pathway in self‐organizing differentiation and co‐cultured them with monocytes under hypoxia/reoxygenation to model myocardial ischemia/reperfusion injury. Through RNA‐seq we found that IFN‐I may be a potential therapeutic target and verified the efficacy of related drug Anifrolumab. Current therapeutic drug exploring targeting at myocardial ischemia/reperfusion (I/R) injury is limited due to the lack of humanized cardiac models that resemble myocardial damage and inflammatory response. Herein, we develop ventricular cardiac organoids from human induced pluripotent stem cells (hiPSCs) and simulate I/R injury by hypoxia/reoxygenation (H/R), which results in increased cardiomyocytes apoptosis, elevated oxidative stress, disrupted morphological structure and decreased beat amplitude. RNA‐seq reveals a potential role of type I interferon (IFN‐I) in this I/R injury model. We then introduce THP‐1 cells and reveal inflammatory responses between monocytes/macrophages and H/R‐induced ventricular cardiac organoids. Furthermore, we demonstrate Anifrolumab, an FDA approved antagonist of IFN‐I receptor, effectively decreases IFN‐I secretion and related gene expression, attenuates H/R‐induced inflammation and oxidative stress in the co‐culture system. This study advances the modelling of myocardial I/R injury with inflammatory response in human cardiac organoids, which provides a reliable platform for preclinical study and drug screening.
cell biology
What problem does this paper attempt to address?